A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection.
A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection.
复制标题
DOI:
10.1186/s12951-022-01467-w
复制
发表时间:
2022-06-03
影响因子:
10.2
通讯作者:
Liu, Gang
中科院分区:
文献类型:
--
作者:
He, Pan;Xiong, Yongfu;Ye, Jinfa;Chen, Biaoqi;Cheng, Hongwei;Liu, Hao;Zheng, Yating;Chu, Chengchao;Mao, Jingsong;Chen, Aizheng;Zhang, Yang;Li, Jingdong;Tian, Jie;Liu, Gang
关键词:
Applying traditional fluorescence navigation technologies in hepatocellular carcinoma is severely restricted by high false-positive rates, variable tumor differentiation, and unstable fluorescence performance. In this study, a green, economical and safe nanomedicine formulation technology was developed to construct carrier-free indocyanine green nanoparticles (nanoICG) with a small uniform size and better fluorescent properties without any molecular structure changes compared to the ICG molecule. Subsequently, nanoICG dispersed into lipiodol via a super-stable homogeneous intermixed formulation technology (SHIFT&nanoICG) for transhepatic arterial embolization combined with fluorescent laparoscopic hepatectomy to eliminate the existing shortcomings. A 52-year-old liver cancer patient was recruited for the clinical trial of SHIFT&nanoICG. We demonstrate that SHIFT&nanoICG could accurately identify and mark the lesion with excellent stability, embolism, optical imaging performance, and higher tumor-to-normal tissue ratio, especially in the detection of the microsatellite lesions (0.4 × 0.3 cm), which could not be detected by preoperative imaging, to realize a complete resection of hepatocellular carcinoma under fluorescence laparoscopy in a shorter period (within 2 h) and with less intraoperative blood loss (50 mL). This simple and effective strategy integrates the diagnosis and treatment of hepatocellular carcinoma, and thus, it has great potential in various clinical applications. The online version contains supplementary material available at 10.1186/s12951-022-01467-w.
登录
查看更多内容
影响因子:
2.5
作者:
Gotoh, Kunihito;Yamada, Terumasa;Imaoka, Shingi
通讯作者:
Imaoka, Shingi
影响因子:
--
作者:
Zhang W;Hu Z;Tian J;Fang C
通讯作者:
Fang C
影响因子:
3.1
作者:
Mindt, Sonani;Karampinis, Ioannis;Nowak, Kai
通讯作者:
Nowak, Kai
影响因子:
13.8
作者:
Murakami T;Tsurusaki M
通讯作者:
Tsurusaki M
影响因子:
28.1
作者:
Hu, Zhenhua;Fang, Cheng;Tian, Jie
通讯作者:
Tian, Jie